Lutetium-177-PSMA-617 is now FDA-approved for the treatment of patients with metastatic castration-resistant prostate cancer who have already received androgen receptor pathway inhibition and taxane-based chemotherapy. The FDA has approved lutetium-177 (177Lu)-PSMA-617 (Pluvicto) to treat patien...
Current approval of 177Lu-PSMA-617 177Lu-PSMA-617 is approved by the FDA for the treatment of patients with PSMA-positive mCRPC in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting.2 The approval of LuPSMA was based on findings from the VISION trial, in wh...
Outline 177Lu-PSMA-617 in metastatic castrate resistant prostate cancer Radioligand therapy centres–practical challenges for India and LMICs Future directives for LMICs Contributors Declaration of interests ReferencesThe Lancet Regional Health - Southeast Asia Volume 30, November 2024, 100484Comment...
This initial experience may be biased by number of patients with limited standard of care options at the time of FDA approval of LuPSMA and could improve with better patient selection. However, this also highlights the continued need to develop novel therapeutic strategies for CRPC pts post-Lu...
Arun Azad, MBBS, PhD, FRACP, discusses the rationale that inspired the launch of the UpFrontPSMA trial, and highlights past and future research directions with 177Lu-PSMA-617 in the treatment of patients with prostate cancer. Arun Azad, MBBS, PhD, FRACP Several prosp...
Approval was granted by the ethics committee of the Albert-Ludwigs-University Freiburg (Vote no.: 551/17). Informed consent was obtained from all individual participants included in the study. Consent for publication Patients signed informed consent regarding publishing their data. Competing interests ...
This initial experience may be biased by number of patients with limited standard of care options at the time of FDA approval of LuPSMA and could improve with better patient selection. However, this also highlights the continued need to develop novel therapeutic strategies for CRPC pts post-Lu...
The FDA approval of [177Lu]Lu-PSMA-617 as radioligand therapy (RLT) for the management of progressive mCRPC [46] was simultaneously accompanied by the approval of the diagnostic radiopharmaceutical [68Ga]Ga-PSMA-11, to assess the eligibility of this treatment in these patients [27]. ...
Correspondence toMuhammad Numair Younis. Ethics declarations Conflict of interest The authors declare no competing interests. Ethical approval The present study was approved by the Institutional Ethics Committee of Institute of Nuclear Medicine and Oncology Lahore, Punjab, Pakistan (INM-022/NM-30) and ...
During 177Lu–PSMA therapy, co-administration of ARPI occurred in 10/24 (23.8%) of patients.Conclusions:This study highlights the differences in quality metrics between patients who received 177Lu–PSMA therapy in a real-world practice setting compared to the FDA label for this agent and VISION...